KR950007250B1 - Process for preparing saponin - Google Patents
Process for preparing saponin Download PDFInfo
- Publication number
- KR950007250B1 KR950007250B1 KR1019920006242A KR920006242A KR950007250B1 KR 950007250 B1 KR950007250 B1 KR 950007250B1 KR 1019920006242 A KR1019920006242 A KR 1019920006242A KR 920006242 A KR920006242 A KR 920006242A KR 950007250 B1 KR950007250 B1 KR 950007250B1
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- sugar
- sodium
- structural formula
- potassium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/48—Silver or gold
- B01J23/50—Silver
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
- B01J23/76—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36
- B01J23/80—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups B01J23/02 - B01J23/36 with zinc, cadmium or mercury
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
Description
본 발명은 구조식(Ⅰ)로 표시되는 인삼 사포닌인 진세노사이드 Rh2를 제조하는 방법에 관한 것이다.The present invention relates to a method for preparing ginsenoside Rh 2 which is ginseng saponin represented by structural formula (I).
[화학식 1][Formula 1]
또한, 본 발명의 목적은 항암작용이 있는 인산 사포닌인 구조식(Ⅰ)에 대해 새롭고 진보된 제조방법을 제공하는 것이다.It is also an object of the present invention to provide a new and advanced preparation method for the structural formula (I), which is saponin phosphate with anticancer activity.
간단히 설명하면 백삼, 인삼엽 또는 돌외로부터 비당부인 20(S)-프로토파낙사디올율 추출, 분리하여 구조식(Ⅰ)의 인삼사포닌인 진세노사이드 Rh2를 제조하는 방법에 관한 것이다.Briefly, the present invention relates to a method for preparing ginsenoside Rh 2 , which is ginseng saponin of structural formula (I), by extracting and isolating non-sugar 20 (S) -protopanaxadiol ratio from white ginseng, ginseng leaf or Dol et al.
본 발명에 의하여 제조되어지는 구조식(Ⅰ)의 화합물은 오다시마 등(Odashima, et al., 일본특허공보 89-28759)이 홍삼으로부터 분리, 구조 결정한 광범위한 항암효과가 있는 인삼 사포닌으로 부작용과 독성이 거의 없는 것으로 알려져 있다. 또한, 아베등(Abe, et al., 신편생물활성천연물질, 제5장, 316, 1988)은 상기 물질의 간염치료 활성을 보고하였다.The compound of formula (I) prepared by the present invention is a ginseng saponin having a wide range of anticancer effects, isolated and structured from red ginseng by Odashima et al. (Japanese Patent Publication No. 89-28759). Little is known. In addition, Abe et al., New Biologically Active Naturals, Chapter 5, 316, 1988 reported the hepatitis therapeutic activity of these substances.
그러나 기타가와등(Kitagawa, et al., 일본약학잡지, 103, 612, 1983)에 의하면 상기 구조식(Ⅰ)의 화합물은 백삼에는 존재하지 않고 홍삼에만 미량으로 존재하는 성분으로 알려져 있다.However, according to Kitagawa et al. (Japan Pharmaceutical Magazine, 103, 612, 1983), the compound of formula (I) is known to be present in trace amounts only in red ginseng, not in white ginseng.
따라서, 순수한 구조식(Ⅰ)의 화합물을 다량으로 얻을 수 있는 방법이 필요하게 됐으며, 일본특허공보89-28759에서 화학적인 처리를 하여 구조식(Ⅰ)의 화합물을 분리하였으나 그 수율이 0.01%로 만족스럽지 못하다. 이에 본 발명자등은 구조식(Ⅰ)의 비당부가 20(S)-프로토파낙사디올인점에 착안하여 20(S)-프로토파낙사디올을 다량 함유하고 있는 홍삼보다 가격이 싼 백삼, 인삼엽 또는 돌외에서 비당부를 얻고 이를 배당체화하면 구조식(Ⅰ)의 화합물을 높은 수율로 얻을 수 있다는 것을 발견하였다.Therefore, there is a need for a method for obtaining a large amount of pure compound of formula (I), and the compound of structure (I) was isolated by chemical treatment in Japanese Patent Publication No. 89-28759, but the yield was not satisfactory at 0.01%. Can not do it. Therefore, the present inventors focus on the fact that the non-sugar portion of Structural Formula (I) is 20 (S) -protopanaxadiol, and white ginseng and ginseng leaf which are cheaper than red ginseng containing a large amount of 20 (S) -protopanaxadiol. Alternatively, it was found that by obtaining a non-glycoside in a stone and glycosides it, the compound of formula (I) can be obtained in high yield.
구조식(Ⅰ)의 진성 비당부를 얻기 위한 방법으로 시바타등(Shibata, et al., Chem, Pharm. Bull., 20, 1212, 1972)은 산 가수분해 반응을 이용하였으나, 이 방법은 비당부의 2차적인 변환에 의한 부산물(artifact)이 생성된다.Shibata et al. (Shibata, et al., Chem, Pharm. Bull., 20, 1212, 1972) used an acid hydrolysis reaction as a method for obtaining the intrinsic fructose of structural formula (I). Secondary transformations produce artifacts.
또, 기타가와등(Kitagawa, et al., Tetrahedron Letters, 30, 2283, 1974)은 토양균 가수분해법을, 디메이어등(De Mayo, et al., Canad. J. Chem., 43, 2033, 1965)은 디메이어 분해법을 제시하고 있으나 모두 그 방법이 복잡하거나, 수율이 좋지 않다. 그리고 조 추출물의 제조시 일반적인 방법을 사용할 경우 공정이 복잡하고 목적 성분의 손실등이 일어날 수 있다.In addition, Kitagawa et al. (Tetrahedron Letters, 30, 2283, 1974) used soil bacteria hydrolysis, De Mayo, et al., Canad. J. Chem., 43, 2033. (1965) suggests Demeier decomposition, but all are complex or have poor yields. In addition, when the general method is used in the preparation of the crude extract, the process may be complicated and loss of the target ingredient may occur.
또한, 배당체의 합성 방법으로는 1901년 Koenigs-Knorr법(Koenigs, W., and Knorr, E., Ber., 34, 957, 1901)이 보고된 이후 많은 방법이 보고 되었으나, 반응 원료에 따라 특이적이거나 반응조건등이 까다롭다.In addition, many methods have been reported since the synthesis of glycosides since the Koenigs-Knorr method (Koenigs, W., and Knorr, E., Ber., 34, 957, 1901) was reported in 1901. Enemy or difficult reaction conditions.
더구나 구조식(Ⅰ)의 비당부의 경우는 열에 불안정하여 가열하는 조건으로는 배당체를 합성할 수 없다.Moreover, in the case of non-sugar parts of the structural formula (I), glycosides cannot be synthesized under conditions of heating because of heat instability.
따라서, 본 발명의 목적은 추출과 동시에 구조식(Ⅰ)의 비당부를 다량으로 제조하고 이것을 사용하여 완화한 조건에서 활성을 갖는 구조식(Ⅰ)인 인삼 사포닌을 제조하는 방법을 제공하고 있다.Accordingly, an object of the present invention is to provide a method for preparing ginseng saponin, which is a structural formula (I) having an activity under mild conditions by extracting a large amount of the non-sugar portion of the structural formula (I) simultaneously with extraction.
본 발명을 간단히 설명하면 백삼, 인삼염 또는 돌외의 조말로 부터 추출과 동시에 완전 알카리 분해하여 구조식(Ⅰ)의 비당부를 2차적인 변화없이 다량으로 제조하고, 이것을 탄산은과 탄산카드뮴의 혼합촉매존재하 브롬당과 배당체화 반응을 시킨 후 잔여 아세틸기를 제거하여 구조식(Ⅰ)의 화합물을 높은 수율로 얻을 수 있는 방법이다(총수율 0.6%(w/w))Briefly describing the present invention, extraction from white ginseng, ginseng salt or dolol other crudes and complete alkali decomposition to prepare a large amount of non-sugar parts of the structural formula (I) without a secondary change, this is a mixed catalyst of silver carbonate and cadmium carbonate It is a method to obtain the compound of formula (I) in high yield by performing glycoside reaction with bromine sugar in the presence of (I) (total yield 0.6% (w / w))
이를 보다 자세히 설명하면 다음과 같다.This will be described in more detail as follows.
백삼, 인삼염 또는 돌외를 조발로 하여 이것을 저급 알콜과 강알칼리를 이용하여 추출과 동시에 유욕상에서 완전 알카리 분해하여 구조식(Ⅰ)의 진성 비당분인 20(S)-프로노파낙사디올을 얻는다.White ginseng, ginseng salt or dolot is used as a coarse extract, which is extracted with lower alcohol and strong alkali, and completely alkaline decomposed in an oil bath to obtain 20 (S) -propanoparanadiol, which is a true non-sugar of structural formula (I).
이때 저급 알콜로는 무수메탄올, 무수에탄올 또는 무수부탄올이, 강알카리로는 금속나트륨, 수산화칼륨, 수산화나트륨, 나트륨 메톡사이드, 나트륨 에톡사이드, 칼륨 메톡사이드 또는 칼륨 에톡사이드가 적당하다.At this time, as the lower alcohol, anhydrous methanol, anhydrous ethanol or anhydrous butanol is suitable, and as strong alkali, metal sodium, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, potassium methoxide or potassium ethoxide is suitable.
위에서 얻은 비당부인 20(S)-프로토파낙사디올을 탄산은과 탄산카드뮴의 혼합촉매 존재하 브롬당과 배당체화 반응시킨후, 0.2N-탄산칼륨/80% 수성메탄올을 이용 잔여 아세틸기를 제거하여 구조식(Ⅰ)의 인삼 사포닌을 얻는다.After 20 (S) -protopanaxadiol, which is obtained from above, is glycosided with bromine sugar in the presence of a mixed catalyst of silver carbonate and cadmium carbonate, the remaining acetyl group is removed using 0.2 N-potassium carbonate / 80% aqueous methanol. To obtain ginseng saponin of formula (I).
본 발명의 특징을 요약 설명하면 다음과 같다.The features of the present invention are summarized as follows.
첫째 : 구조식(Ⅰ)의 비당부를 완전 알카리 분해에 의해 생약 원료로 부터 제조하고, 이를 배당체화 반응시켜 구조식(Ⅰ)의 화합물로 높은 수율로 얻을 수 있는 방법이다.Firstly, non-sugar part of structural formula (I) is prepared from herbal raw materials by complete alkali decomposition, and glycoside reaction is performed to obtain high yield of compound of structural formula (Ⅰ).
둘째 : 구조식(Ⅰ)의 비당부를 제조시 추출과 동시에 알카리 분해하여 일반적 추출 공정을 단축함으로써 훨씬 경제적이다.Second: It is much more economical by shortening the general extraction process by decomposing alkali at the same time as extraction in manufacturing non-sugar part of structural formula (Ⅰ).
셋째 : 구조식(Ⅰ)의 비당부를 진성 비당부로 가지는 모든 생약으로 부터 쉽게 제조 가능하다.Third: It can be easily manufactured from all herbal medicines having the non-sugar portion of structural formula (I) as an intrinsic non-sugar portion.
넷째 : 배당체화 반응시 혼합 촉매를 사용한 완화한 조건으로 합성법이다.Fourth: in the moderated conditions using a mixed catalyst during glycoside reaction, it is a synthesis method.
본 발명에 의한 구조식(Ⅰ)의 인삼 사포닌을 제조하는 구체적인 예는 다음의 실시예에서 상세히 기술하며 본 발명이 다음의 기재에 의하여 한정되어 있는 것은 아니다.Specific examples of preparing ginseng saponin of formula (I) according to the present invention will be described in detail in the following examples, and the present invention is not limited by the following description.
[실시예 1]Example 1
20(S)-프로토파낙사디올의 추출, 정제Extraction and purification of 20 (S) -protopanaxadiol
인산염 100g을 조말로 하여, 이것을 빙욕중의 무수 에탄올 800ml에 나트륨메톤사이드(Aldrich. 16, 499-2) 60g을 소량씩 가하여 완전히 녹인 반응용 시액에 가한다.100 g of phosphate is prepared as a crude powder. To 800 ml of anhydrous ethanol in an ice bath, 60 g of sodium methoxide (Aldrich. 16, 499-2) is added in small portions to a completely dissolved reaction solution.
반응액을 유욕상에서 교반하면서 48시간 가열 환류 반응시킨다. 반응 완결후 증류수 800ml를 가하고, 이것을 에틸아세테이트 800ml로 3회 추출한다. 에틸아세테이트층을 분리하여 얻고 이것을 포화 염화나트륨 1500ml의 수용액으로 중화한다. 다시 증류수 1500ml를 가하여 수세하고, 에틸아세테이트층을 무수 황산마그네슘으로 탈수하고 여과한다.The reaction solution is heated to reflux for 48 hours with stirring on an oil bath. After completion of the reaction, 800 ml of distilled water was added, which was extracted three times with 800 ml of ethyl acetate. The ethyl acetate layer was isolated and neutralized with an aqueous solution of 1500 ml of saturated sodium chloride. Then, 1500 ml of distilled water was added, and the mixture was washed with water, and the ethyl acetate layer was dehydrated with anhydrous magnesium sulfate and filtered.
여액을 감압증발시켜 건조 분해 생성물 5g을 얻는다.The filtrate is evaporated under reduced pressure to give 5 g of dry decomposition products.
이것을 n-헥산-아세톤(1:2)의 혼합용액 24ml로 완전히 용해 시킨 후 실리카겔(Merck, 70-230mesh) 6g을 넣고 감압건조시켜 실리카겔에 완전히 흡착시킨다. 흡착시킨것을 따로 실리카겔(Merck, 70-230mesh) 390g으로 충전시킨 칼럼 상부에 가한다.After completely dissolving this in 24 ml of a mixed solution of n-hexane-acetone (1: 2), 6 g of silica gel (Merck, 70-230mesh) was added thereto, dried under reduced pressure, and completely adsorbed onto the silica gel. The adsorbate was separately added to the top of the column packed with 390 g of silica gel (Merck, 70-230mesh).
계속하여 n-헥산-아세톤(5:1)의 혼합용매로 용출시켜 그 분획을 얻고, 감압증류 및 결정화에 의해 살기표제 화합물 720mg을 얻는다.(수율 0.72%(w/w))Subsequently, the mixture was eluted with a mixed solvent of n-hexane-acetone (5: 1) to obtain a fraction, and 720 mg of the title compound was obtained by distillation under reduced pressure and crystallization (yield 0.72% (w / w)).
1H-NMR(CDCl3,δ) : 0.78(3H, S), 0.88(6H, S), 0.98(6H, S), 1.16(3H, S), 1.61, 1.68(3H each, boths)…8×-CH3, 2.8,3.2,3.6(1H each, broad S, 3×-OH), 5.16(1H, t-like, C24-H). 1 H-NMR (CDCl 3 , δ): 0.78 (3H, S), 0.88 (6H, S), 0.98 (6H, S), 1.16 (3H, S), 1.61, 1.68 (3H each, boths). 8 × -CH 3 , 2.8,3.2,3.6 (1H each, broad S, 3 × -OH), 5.16 (1H, t-like, C 24 -H).
13C-NMR(pyridine-d5,δ) : 78.1(C-3), 71.0(C-12), 54.8(C-17), 73.0(C-20), 27.1(C-21), 35.9(C-22), 126.3(C-24), 130.7(C-25). 13 C-NMR (pyridine-d 5 , δ): 78.1 (C-3), 71.0 (C-12), 54.8 (C-17), 73.0 (C-20), 27.1 (C-21), 35.9 ( C-22), 126.3 (C-24), 130.7 (C-25).
[실시예 2]Example 2
진세노사이드 Rh2의 제조Preparation of Ginsenoside Rh 2
실시예 1에서 분리한 표제화합물 200mg(0.43mmole)에 디클로로메탄 20ml을 가하여 녹인다. 반응조를 차광한 후 여기에 탄산은 142mg(0.52mmole, 1.2eq.)과 탄산카드뮴 82mg(0.47mmole, 1.1eq.)을 가하고 5분간 실온에서 교반한다.20 mg of dichloromethane was dissolved in 200 mg (0.43 mmol) of the title compound isolated in Example 1. After shielding the reaction tank, 142 mg (0.52 mmol, 1.2 eq.) Of carbonate and 82 mg (0.47 mmol, 1.1 eq.) Of cadmium carbonate were added thereto and stirred at room temperature for 5 minutes.
계속하여 브롬당 270mg(0.65mmole, 1.5eq.)을 가하고 실온에서 35분간 교반한다. 반응완결을 확인한 후 반응조를 디클로로메탄 40ml로 희석하여 여과하고, 감압 건조시켜 조 생성물 400mg을 얻는다.Then add 270 mg (0.65 mmol, 1.5 eq.) Per bromine and stir at room temperature for 35 minutes. After confirming the reaction, the reaction vessel was diluted with 40 ml of dichloromethane, filtered, and dried under reduced pressure to obtain 400 mg of crude product.
여기에 실리카겔(Merck, 70-230mesh) 500mg을 가하여 조 생성물을 실리카겔에 완전히 흡착시키고, 따로 실리카겔(Merck, 70-230mesh) 35g으로 충전시킨 칼럼 상부에 가한다. 이것을 n-헥산-아세톤(4:1)의 혼합용매로 용출시켜 그 분획을 얻고, 용매를 감압증발시킨 뒤, 클로로포름-메탄올을 이용 재결정화에 의해 무색 침상의 3-0-(2',3',4',6'-테트라-O-아세틸-β-D-글루코피라노실)-20(S)-프로토파낙사디올 160mg을 얻는다.(수율 46.6%)To this, 500 mg of silica gel (Merck, 70-230mesh) was added, and the crude product was completely adsorbed onto the silica gel and separately added to the top of the column filled with 35 g of silica gel (Merck, 70-230mesh). This was eluted with a mixed solvent of n-hexane-acetone (4: 1) to obtain a fraction. The solvent was evaporated under reduced pressure, and then recrystallized with chloroform-methanol to give a colorless needle of 3-0- (2 ', 3). 160 mg of ', 4', 6'-tetra-O-acetyl-β-D-glucopyranosyl) -20 (S) -protopanaxadiol was obtained (yield 46.6%).
1H-NMR(CDCl3,δ) : 0.81-1.69(8×-CH3), 1.98(3H,S), 2.02(6H,S), 2.09(3H,S)…4×-OAc, 4.67(1H,d,J=7.2Hz, Anomeric Proton), 5.07(1H,t-like, C24-H). 1 H-NMR (CDCl 3 , δ): 0.81-1.69 (8 × CH 3 ), 1.98 (3H, S), 2.02 (6H, S), 2.09 (3H, S). 4x-OAc, 4.67 (1H, d, J = 7.2 Hz, Anomeric Proton), 5.07 (1H, t-like, C 24 -H).
위에서 얻어진 무색침사이결정 80mg을 0.2N-탄산칼륨/80% 수성메탄올 8ml에 녹이고 2시간 실온에서 교반시켜 탈 아세틸화 한다.80 mg of the colorless needles obtained above are dissolved in 8 ml of 0.2 N-potassium carbonate / 80% aqueous methanol and stirred at room temperature for 2 hours to deacetylate.
이것을 Dowex 50W×8(H+)로 중화하고 여과한 후, 여액을 n-부탄올 10ml로 추출한다. n-부탄올층을 분리하여 얻고 이를 감압건조시킨 뒤 결정화에 의해 상기 표제화합물 75mg을 얻는다.This is neutralized with Dowex 50W × 8 (H + ), filtered, and the filtrate is extracted with 10 ml of n-butanol. The n-butanol layer was separated and dried under reduced pressure to give 75 mg of the title compound by crystallization.
13C-NMR(pyridine-d5,δ) : 88.9(C-3), 71.1(C-12), 73.2(C-20), 126.4(C-24), 130.1(C-25), 106.5(D-glucose부분, C-1'), 75.8(C-2'), 78.7(C-3'), 72.3(C-4'), 78.0(C-5'), 63.5(C-6'). 13 C-NMR (pyridine-d5, δ): 88.9 (C-3), 71.1 (C-12), 73.2 (C-20), 126.4 (C-24), 130.1 (C-25), 106.5 (D -glucose moiety, C-1 '), 75.8 (C-2'), 78.7 (C-3 '), 72.3 (C-4'), 78.0 (C-5 '), 63.5 (C-6').
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019920006242A KR950007250B1 (en) | 1992-04-15 | 1992-04-15 | Process for preparing saponin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019920006242A KR950007250B1 (en) | 1992-04-15 | 1992-04-15 | Process for preparing saponin |
Publications (2)
Publication Number | Publication Date |
---|---|
KR930021652A KR930021652A (en) | 1993-11-22 |
KR950007250B1 true KR950007250B1 (en) | 1995-07-07 |
Family
ID=19331784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920006242A KR950007250B1 (en) | 1992-04-15 | 1992-04-15 | Process for preparing saponin |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR950007250B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006010307A1 (en) * | 2004-07-29 | 2006-02-02 | Shanghai Innovative Research Center Of Traditional Chinese Medicine | A synthetic method of 20 (s)-ginsenoside rh2 |
CN102532234A (en) * | 2010-12-10 | 2012-07-04 | 北京本草天源药物研究院 | Method for extracting and purifying ginsenoside Rg1 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101009941B1 (en) * | 2008-11-20 | 2011-01-20 | 김진칠 | A Liquid, Capsule and Ample Manufacturing Method Using saponin from Gynostemma pentaphyllum |
-
1992
- 1992-04-15 KR KR1019920006242A patent/KR950007250B1/en not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006010307A1 (en) * | 2004-07-29 | 2006-02-02 | Shanghai Innovative Research Center Of Traditional Chinese Medicine | A synthetic method of 20 (s)-ginsenoside rh2 |
KR100913010B1 (en) * | 2004-07-29 | 2009-08-20 | 상하이 이노베티브 리서치 센터 오브 트레디셔날 차이니스 메디슨 | A synthetic method of 20 s-ginsenoside rh2 |
CN102532234A (en) * | 2010-12-10 | 2012-07-04 | 北京本草天源药物研究院 | Method for extracting and purifying ginsenoside Rg1 |
Also Published As
Publication number | Publication date |
---|---|
KR930021652A (en) | 1993-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU902666A3 (en) | Method of preparing pleuromutiline glycoside derivatives | |
EP0369182B1 (en) | Antitumour saccharide conjugates | |
EP0041355A1 (en) | Novel erythromycin compounds | |
KR100418604B1 (en) | Manufacturing method of Compound K and Ginsenoside F1 from ginseng ginsenosides | |
WO1998040390A2 (en) | Oligosaccharides and the derivatives thereof, chemo-enzymatic method for the production thereof | |
KOIZUMI et al. | Studies on the saponins of Ginseng. IV. On the structure and enzymatic hydrolysis of ginsenoside-Ra1 | |
EP0114954B1 (en) | Derivatives and reduction products of d-glucopyranosyl-alpha(1-5)-d-arbonic acid, their preparation and use | |
EP0021231B1 (en) | Process for the preparation of 5'-deoxy-5-fluoro uridine and intermediates in this process | |
Nohara et al. | Study on the constituents of Paris quadriforia L. | |
Riccio et al. | Starfish Saponins, Part 22. Asterosaponins from the Starfish Halityle regularis: A Novel 22, 23-Epoxysteroidal Gylcoside Sulfate | |
CH500183A (en) | Epipodophyllotoxin benzylidene-beta-d-glucoside | |
KR950007250B1 (en) | Process for preparing saponin | |
KR20000045694A (en) | Method for producing 20(s)-ginsenoside rh2 | |
Mizutani et al. | NMR-spectral studies of 2-linked glycosides: 2-O-glycosylation shifts of 2-O-glycosylated α-and β-l-arabinopyranosides | |
DE60310723T2 (en) | METHOD AND NEW INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF STEROLS WITH A PROGESTERIC ACTIVITY | |
KR930005989B1 (en) | Preparation of |3-0-(2',3',4',6'-tetra-0-acetyl-beta-d-glucopyranosyl)-20(s)-protopanaxadiol¨ | |
KR100186757B1 (en) | Preparation process of 20(s)-ginsenocide rh1 and 20(s)-protopanaxtrlyol | |
NZ226888A (en) | Sialocylglycerolipids and their method of preparation | |
KR100654172B1 (en) | A preparation method of ginsenoside Mc and Mc-1 | |
KR100218553B1 (en) | Process for producing ginsenoside rg3 | |
Ghosal et al. | Phosphatidylpyrrolophenanthridine alkaloids from Zephyranthes flava | |
DE3719377A1 (en) | ANTHRACYCLINGLYCOSIDES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THEIR USE AS ANTITUARY MEDICINES | |
ABE et al. | Affinosides M and K, cardenolide glycosides from the seeds of Anodendron affine (Anodendron. V) | |
Koto et al. | In situ Activating Glycosylation of 6-Deoxysugars: Synthesis of O-. ALPHA.-D-Fucosyl-(1. RAR. 4)-O-. ALPHA.-D-fucosyl-(1. RAR. 4)-O-. ALPHA.-D-quinovosyl-(1. RAR. 4)-D-quinovose. | |
KR19980027403A (en) | Method for preparing 20 (S) -ginsenoside Rg₂ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |